Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten versus placebo in adults with symptomatic obstructive hypertrophic cardiomyopathy
NL-OMON50292Phase 3Completed
- Sponsor
- MyoKardia
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoint: Clinical response. Started Mar 2019; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON50292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50292.